The effect of burosumab (KRN23), a fully human anti-FGF23 monoclonal antibody, on osteomalacia in adults with x-linked hypophosphatemia (XLH)

Authors
Category Primary study
JournalJournal of Bone and Mineral Research
Year 2018
This article has no abstract
Epistemonikos ID: f30625519b6b863fe29d8175bb913926c368fb6d
First added on: Feb 11, 2025